Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:11 PM
Ignite Modification Date:
2025-12-24 @ 9:11 PM
NCT ID:
NCT04552704
Eligibility Criteria:
Inclusion Criteria:
* Ability to understand and willingness to sign an informed consent form
* At least 18 years of age
* Histologically confirmed advanced solid tumors
* Patients must have grade 2 or 3 irAEs from at least one ICI-containing regimen. Both newly emerging and persistent irAEs are allowed. Systemic steroid therapy or any other form of immunosuppressive therapy for irAEs is allowed. The specific irAEs are
* Grade 2-3 diarrhea/colitis: Patients with \>= 4 stools per day or moderate-severe increase in ostomy output compared to baseline but not life-threatening diarrhea
* Grade 2-3 pneumonitis: Mild to moderate (grade 2) or severe (grade 3) symptoms (including hypoxia, shortness of breath, requiring oxygen) but not life-threatening respiratory compromise requiring urgent intervention (e.g., tracheostomy or intubation)
* Grade 2-3 renal irAE: Creatine increased between 1.6-6.0 x upper limit of normal (ULN) or =\< 3.0 x baseline if baseline was abnormal, estimated glomerular filtration rate (eGFR) or creatinine clearance \>= 15 ml/min/1.73m\^2 but not life-threatening consequences or requiring dialysis
* Grade 2-3 Hepatic irAE: AST/ALT/ALP levels 3-20 x ULN, and T bilirubin increased \<5 x ULN
* Grade 2-3 skin rash: moderate (10-30% body surface area, BSA) to severe (\> 30% BSA) but not life-threatening skin lesions or Stevens-Johnson syndrome
* Eastern Cooperative Oncology Group (ECOG) performance status \< 2
* Life expectancy of \>= 3 months at the time of enrollment
* Pretreatment absolute neutrophil count (ANC) \>= 1,000/uL obtained within 14 days prior to 1st dose of treatment
* Pretreatment hemoglobin \>= 8 gm/dL obtained within 14 days prior to 1st dose of treatment
* Pretreatment platelet count of \>= 75,000/uL obtained within 14 days prior to 1st dose of treatment
* Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for \>= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Or, female subjects of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first study drug administration
* Male and female subjects who agree to use highly effective method of birth control (e.g., implants, injectables, birth control pills with two hormones, intrauterine devices \[IUDs\], complete abstinence or sterilized partner, and female sterilization) and a barrier method (e.g., condoms, vaginal ring, sponge, etc.) during the period of therapy and for 90 days after the last dose of study drug
Exclusion Criteria:
* Prior CD24Fc therapy
* Any known active hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, including patients who have an active infection requiring systemic therapy. History of COVID-19 or known asymptomatic carrier of SARS-CoV-2 virus is allowed
* Pregnant or lactating women
* Any medical condition including additional laboratory abnormalities, or psychiatric illness that would, in the opinion of the investigator, prevent the subject from participating and adhering to study related procedures
* Any known severe bacterial, fungal, or viral infection that in the opinion of the investigator would interfere with patient safety or compliance on trial within 2 weeks prior to enrollment
* Patients with concomitant proarrhythmic medications
* Patients with heart failure in New York (NY) Heart Association stage IV
* Any grade 4 irAE symptoms and Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 grade 4 toxicity
* AST, ALT, gamma glutamyl transpeptidase (GGT), or ALP \> 20.0 x ULN regardless of baseline
* Blood bilirubin \>5.0 x ULN regardless of baseline
* Creatinine \> 6.0 x ULN or creatinine clearance \<15 ml/min/1.73m2
* Urine: Anuria \< 140 ml in 24 hours
* Electrolytes hyponatremia, sodium \< 120 mmol/L
* Hypokalemia, potassium \< 2.5 mmol/L
* Creatine kinase (CPK) \> 10.0 ULN
* Electrocardiogram (ECG): Prolonged QT interval \>= 480 mS, corrected by Fridericia's formula. Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrythmia
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04552704
Study Brief:
Protocol Section:
NCT04552704